Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $184 | $108 | $123 | $122 |
| Short-Term Investments | $60 | $98 | $68 | $60 |
| Receivables | $42 | $21 | $20 | $4 |
| Inventory | $26 | $31 | $22 | $4 |
| Other Curr. Assets | $20 | $18 | $11 | $7 |
| Total Curr. Assets | $332 | $276 | $243 | $196 |
| Property Plant & Equip (Net) | $11 | $13 | $7 | $8 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $16 | $17 | $18 | $19 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $211 | $219 | $185 | $0 |
| Other NC Assets | $10 | $1 | $6 | $9 |
| Total NC Assets | $249 | $250 | $217 | $36 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $581 | $526 | $460 | $233 |
| Liabilities | – | – | – | – |
| Payables | $2 | $8 | $8 | $2 |
| Short-Term Debt | $2 | $2 | $3 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $97 | $53 | $36 | $40 |
| Total Curr. Liab. | $101 | $64 | $47 | $45 |
| LT Debt | $8 | $10 | $3 | $3 |
| Deferred Rev, NC | $32 | $12 | $12 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $2 | $2 | $0 |
| Total NC Liab. | $41 | $24 | $16 | $3 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $10 | $12 | $6 | $6 |
| Total Liabilities | $142 | $87 | $64 | $48 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$521 | -$478 | -$492 | -$675 |
| AOCI | -$0 | $0 | $0 | -$0 |
| Other Equity | $960 | $917 | $888 | $860 |
| Total Equity | $438 | $439 | $396 | $185 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $581 | $526 | $460 | $233 |
| Net Debt | -$174 | -$96 | -$117 | -$116 |